These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11329854)

  • 21. [Glitazones (thiazolidinedione)].
    Ducobu J; Sternon J
    Rev Med Brux; 2000 Oct; 21(5):441-6. PubMed ID: 11109896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mechanisms by which PPAR gamma modulators regulate insulin sensitivity].
    Yamauchi T; Kadowaki T
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():578-87. PubMed ID: 12387054
    [No Abstract]   [Full Text] [Related]  

  • 23. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
    Ma LJ; Marcantoni C; Linton MF; Fazio S; Fogo AB
    Kidney Int; 2001 May; 59(5):1899-910. PubMed ID: 11318962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of glial cell proinflammatory activities by peroxisome proliferator-activated receptor gamma agonist confers partial protection during antimyelin oligodendrocyte glycoprotein demyelination in vitro.
    Duvanel CB; Honegger P; Pershadsingh H; Feinstein D; Matthieu JM
    J Neurosci Res; 2003 Jan; 71(2):246-55. PubMed ID: 12503087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance.
    Patsouris D; Müller M; Kersten S
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1045-50. PubMed ID: 15535425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pharmacology of PPARalpha, PPARgamma and dual PPARalpha/gamma agonists in clinical development].
    Duran-Sandoval D; Thomas AC; Bailleul B; Fruchart JC; Staels B
    Med Sci (Paris); 2003; 19(8-9):819-25. PubMed ID: 14593612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys.
    Gee MK; Zhang L; Rankin SE; Collins JN; Kauffman RF; Wagner JD
    Metabolism; 2004 Sep; 53(9):1121-5. PubMed ID: 15334371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aryloxazolidinediones: identification of potent orally active PPAR dual alpha/gamma agonists.
    Desai RC; Gratale DF; Han W; Koyama H; Metzger E; Lombardo VK; MacNaul KL; Doebber TW; Berger JP; Leung K; Franklin R; Moller DE; Heck JV; Sahoo SP
    Bioorg Med Chem Lett; 2003 Oct; 13(20):3541-4. PubMed ID: 14505666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use?
    Starkey K; Heufelder A; Baker G; Joba W; Evans M; Davies S; Ludgate M
    J Clin Endocrinol Metab; 2003 Jan; 88(1):55-9. PubMed ID: 12519830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach.
    Bays H; Mandarino L; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Feb; 89(2):463-78. PubMed ID: 14764748
    [No Abstract]   [Full Text] [Related]  

  • 31. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model.
    Kim SK; Zhao ZS; Lee YJ; Lee KE; Kang SM; Choi D; Lim SK; Chung N; Lee HC; Cha BS
    Diabetes Metab Res Rev; 2003; 19(6):487-93. PubMed ID: 14648808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Rosiglitazone(BRL-49653)].
    Yonezawa N; Oka Y
    Nihon Rinsho; 2001 Nov; 59(11):2195-9. PubMed ID: 11712407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation.
    Kielian T; Drew PD
    J Neurosci Res; 2003 Feb; 71(3):315-25. PubMed ID: 12526021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
    Wang M; Tafuri S
    J Cell Biochem; 2003 May; 89(1):38-47. PubMed ID: 12682906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel peroxisome proliferator-activated receptor (PPAR)gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPARgamma activation.
    Yotsumoto T; Naitoh T; Kanaki T; Matsuda M; Tsuruzoe N
    Metabolism; 2003 Dec; 52(12):1633-7. PubMed ID: 14669169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes.
    Liang F; Wang F; Zhang S; Gardner DG
    Endocrinology; 2003 Sep; 144(9):4187-94. PubMed ID: 12933694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biology and toxicology of PPARgamma ligands.
    Tugwood JD; Montague CT
    Hum Exp Toxicol; 2002 Aug; 21(8):429-37. PubMed ID: 12412636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
    Brooks DA; Etgen GJ; Rito CJ; Shuker AJ; Dominianni SJ; Warshawsky AM; Ardecky R; Paterniti JR; Tyhonas J; Karanewsky DS; Kauffman RF; Broderick CL; Oldham BA; Montrose-Rafizadeh C; Winneroski LL; Faul MM; McCarthy JR
    J Med Chem; 2001 Jun; 44(13):2061-4. PubMed ID: 11405642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Current topics in the regulation of prostanoids--4. The feedback regulation by PPAR-gamma].
    Ohara M; Sawa T
    Masui; 1999 Feb; 48(2):146-51. PubMed ID: 10087822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [New antidiabetic in "virtual reality". Eye to eye with insulin resistance].
    MMW Fortschr Med; 2000 May; 142(19):52. PubMed ID: 10850084
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.